Anthony MBA - Celldex Therapeutics President, Founder
| CLDX Stock | USD 27.89 1.13 4.22% |
Insider
Anthony MBA is President, Founder of Celldex Therapeutics
| Age | 62 |
| Address | Perryville III Building, Hampton, NJ, United States, 08827 |
| Phone | 908 200 7500 |
| Web | https://www.celldex.com |
Celldex Therapeutics Management Efficiency
The company has return on total asset (ROA) of (0.1973) % which means that it has lost $0.1973 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.2984) %, meaning that it created substantial loss on money invested by shareholders. Celldex Therapeutics' management efficiency ratios could be used to measure how well Celldex Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.34 in 2024. Return On Capital Employed is likely to drop to -0.37 in 2024. At this time, Celldex Therapeutics' Total Assets are fairly stable compared to the past year. Total Current Assets is likely to rise to about 453.3 M in 2024, whereas Non Current Assets Total are likely to drop slightly above 31 M in 2024.Similar Executives
| Showing other executives | INSIDER Age | ||
| MS MD | Dyne Therapeutics | 57 | |
| Prof Davis | Avidity Biosciences | N/A | |
| Kevan Shokat | Revolution Medicines | N/A | |
| John Robinson | Cogent Biosciences | 49 | |
| Jennifer Lachey | Keros Therapeutics | 51 | |
| Harpreet Singh | Immatics NV | 49 | |
| Michael Carruthers | Edgewise Therapeutics | 66 | |
| Donna Dea | Aerovate Therapeutics | N/A | |
| Carsten MD | Immatics NV | 57 | |
| Teresa McCarthy | Avidity Biosciences | 60 | |
| Michel MD | MeiraGTx Holdings PLC | N/A | |
| Daniel Pichl | SpringWorks Therapeutics | 40 | |
| Path FRCP | Revolution Medicines | 61 | |
| Paul Stone | Ideaya Biosciences | 60 | |
| Richard BA | MeiraGTx Holdings PLC | 51 | |
| MBA JD | Ventyx Biosciences | 56 | |
| Chris MBA | Crinetics Pharmaceuticals | N/A | |
| Benjamin Dake | Aerovate Therapeutics | 48 | |
| Jeff Knight | Crinetics Pharmaceuticals | 53 | |
| Gene Kim | Dyne Therapeutics | 47 | |
| Sophia MD | Alx Oncology Holdings | 56 | |
Management Performance
| Return On Equity | -0.3 | ||||
| Return On Asset | -0.2 |
Celldex Therapeutics Leadership Team
Elected by the shareholders, the Celldex Therapeutics' board of directors comprises two types of representatives: Celldex Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Celldex. The board's role is to monitor Celldex Therapeutics' management team and ensure that shareholders' interests are well served. Celldex Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Celldex Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Patrick Till, Senior Communications | ||
| Prof Schlessinger, CoFounder Board | ||
| Diane MD, Senior Officer | ||
| Ronald Pepin, Chief Bus. Officer and Sr. VP | ||
| Sam CPA, CFO, VP | ||
| Sam Martin, CFO, Senior Vice President | ||
| Margo MD, Senior Affairs | ||
| Sarah Cavanaugh, Vice President Investor Relations & Corporate Communications | ||
| Freddy Esq, Senior Counsel | ||
| Elizabeth Crowley, Senior Vice President Chief Product Development Officer | ||
| Richard Wright, Chief VP | ||
| Anthony MBA, President, Founder | ||
| Tibor Keler, Founder, Chief Scientific Officer and Executive VP |
Celldex Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Celldex Therapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.3 | ||||
| Return On Asset | -0.2 | ||||
| Operating Margin | (16.34) % | ||||
| Current Valuation | 1.11 B | ||||
| Shares Outstanding | 66.34 M | ||||
| Shares Owned By Institutions | 100.00 % | ||||
| Number Of Shares Shorted | 8.24 M | ||||
| Price To Earning | (2.21) X | ||||
| Price To Book | 2.38 X | ||||
| Price To Sales | 177.96 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Celldex Stock Analysis
When running Celldex Therapeutics' price analysis, check to measure Celldex Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Celldex Therapeutics is operating at the current time. Most of Celldex Therapeutics' value examination focuses on studying past and present price action to predict the probability of Celldex Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Celldex Therapeutics' price. Additionally, you may evaluate how the addition of Celldex Therapeutics to your portfolios can decrease your overall portfolio volatility.